Company Profile
Nexvet Biopharma public limited company and its subsidiaries (the “Company”) is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing novel, species-specific biologics. Biologics are therapeutic proteins derived from biological sources. As a class, biologics have transformed human medicine in recent decades and represent many of the top-selling therapies on the market today. The Company’s platform technology, which it refers to as “PETization,” is an algorithmic approach that enables the Company to rapidly create monoclonal antibodies (“mAbs”) a type of biologic, that are designed to be recognized as “self” or “native” by an animal’s immune system, a property referred to as “100% species-specificity.” PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to cre... more >
Recent Newsmore >
DateTitle
13 April 2017Zoetis to Acquire Nexvet Biopharma, an Innovator in Monoclonal Antibody Therapies for Companion Animals
Purchase price of US$6.72 per share, or approximately US$85 million in aggregate Acquisition to strengthen Zoetis’ pipeline in companion animal therapeutics for chronic pain, a global area estimated at US$400 million annually1 PARSIPPANY, N.J. & TULLAMORE, Ireland--(BUSINESS WIRE)--Apr. 13, 2017-- Zoetis Inc. (NYSE:ZTS) and Nexvet Biopharma plc (Nasdaq:NVET) today announced an agreement in which Zo... 
22 February 2017Nexvet to Present at the Cowen and Company 37th Annual Health Care Conference
DUBLIN, Ireland, Feb. 22, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced that its Chief Executive Officer, Dr. Mark Heffernan, is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston, Massachusetts on Monday, March 6th at 1:20PM ET. Dr. Heffernan will discuss Nexvet’s pivotal-stage clinical programs for chronic pain in cats and dogs, consisting of ranevetmab and frunevetmab; the significant progress made at the Company’s manufac... 
10 February 2017Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2017
DUBLIN, Ireland, Feb. 10, 2017 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced its financial results for the three and six month periods ended December 31, 2016. Recent highlights: Initiated pivotal field efficacy and safety studies of frunevetmab, the Company’s anti-nerve growth factor monoclonal antibody (anti-NGF mAb) in development for the control of pain associated with osteoarthritis in cats Entered into a research collaboration with Genentech Successfull... 
12 December 2016Nexvet Announces Initiation of Pivotal Efficacy Study of Frunevetmab in Cats
DUBLIN, Ireland, Dec. 12, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET) today announced it has initiated a pivotal field efficacy and safety study of frunevetmab, the Company’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy which is being developed as a monthly subcutaneous injectable for the control of pain associated with osteoarthritis in cats. Nexvet expects to report data from both this study and a currently running pivotal target animal safety study of fruneve... 
Featured Items
Download Documentation Nexvet Cowen Health Care Conference Corporate Overview
Stock Quotemore >
NVET (ADS)
Exchange :NASDAQ
Price :$6.60
Change :0.00 (0.00%)
Volume :53,952
Data as of 04/21/17 3:58 p.m. ET
Minimum 20 minute delay
Receive Email AlertsE-mail Alert Icon
Sign up to receive email alerts whenever Nexvet Biopharma plc posts new information to the site. Just enter your email address and click Submit.
 


Data Provided by Thomson Reuters

Nexvet Biopharma

Ireland
Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98
P: + 353 5793 24522

Australia
Level 8, 31 Queen Street
Melbourne 3000
Victoria
P: +61 (3) 9610 4400

United States
275 Post Street
4th Floor
San Francisco, CA 94108

Email: info@nexvet.com